An overview of CAR T-cell clinical trial activity to 2021

Immunotherapy of cancer using chimeric antigen receptor-engineered T-cells has transformed the management of selected haematological malignancies, triggering intense clinical trial activity in this arena. This article summarises trial activity that has been published to date across the spectrum of h...

Descripción completa

Detalles Bibliográficos
Autores principales: Adami, Antonella, Maher, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
TrialsWatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137996/
https://www.ncbi.nlm.nih.gov/pubmed/34056638
http://dx.doi.org/10.1093/immadv/ltab004
_version_ 1783695719612284928
author Adami, Antonella
Maher, John
author_facet Adami, Antonella
Maher, John
author_sort Adami, Antonella
collection PubMed
description Immunotherapy of cancer using chimeric antigen receptor-engineered T-cells has transformed the management of selected haematological malignancies, triggering intense clinical trial activity in this arena. This article summarises trial activity that has been published to date across the spectrum of haematological and solid tumour types.
format Online
Article
Text
id pubmed-8137996
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-81379962021-05-26 An overview of CAR T-cell clinical trial activity to 2021 Adami, Antonella Maher, John Immunother Adv TrialsWatch Immunotherapy of cancer using chimeric antigen receptor-engineered T-cells has transformed the management of selected haematological malignancies, triggering intense clinical trial activity in this arena. This article summarises trial activity that has been published to date across the spectrum of haematological and solid tumour types. Oxford University Press 2021-03-09 /pmc/articles/PMC8137996/ /pubmed/34056638 http://dx.doi.org/10.1093/immadv/ltab004 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Immunology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle TrialsWatch
Adami, Antonella
Maher, John
An overview of CAR T-cell clinical trial activity to 2021
title An overview of CAR T-cell clinical trial activity to 2021
title_full An overview of CAR T-cell clinical trial activity to 2021
title_fullStr An overview of CAR T-cell clinical trial activity to 2021
title_full_unstemmed An overview of CAR T-cell clinical trial activity to 2021
title_short An overview of CAR T-cell clinical trial activity to 2021
title_sort overview of car t-cell clinical trial activity to 2021
topic TrialsWatch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137996/
https://www.ncbi.nlm.nih.gov/pubmed/34056638
http://dx.doi.org/10.1093/immadv/ltab004
work_keys_str_mv AT adamiantonella anoverviewofcartcellclinicaltrialactivityto2021
AT maherjohn anoverviewofcartcellclinicaltrialactivityto2021
AT adamiantonella overviewofcartcellclinicaltrialactivityto2021
AT maherjohn overviewofcartcellclinicaltrialactivityto2021

Ejemplares similares